Last reviewed · How we verify
NCT06689189
Detection of Sepsis Occurrence by Using Blood Fluorescence
trial testing Blood fluorescence metabolite analysis in Sepsis in 800 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Ningbo Medical Center Lihuili Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 24 January 2024 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Blood fluorescence metabolite analysis
Conditions studied
- Sepsis — all drugs for Sepsis →
- Organ Damage — all drugs for Organ Damage →
Sponsor
Ningbo Medical Center Lihuili Hospital
Who can join
18 and older, any sex, with Sepsis or Organ Damage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study adopted a case-control study method to explore a reagent-free, highly sensitive, and frequently screened blood fluorescence metabolite analyzer for sepsis, which can detect the emergence of inflammatory free radicals before organ damage and shorten the diagnosis time of sepsis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06689189
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other Ningbo Medical Center Lihuili Hospital trials
Trials by the same sponsor.
- NCT07572708 — Transcutaneous Electrical Acustimulation (TEA) for the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD) · NA · not yet recruiting
- NCT07368023 — A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoin · not yet recruiting
- NCT07273032 — Clinical Application Research of Combined Therapy in ERAS for Accelerated Orthopedic Rehabilitation · Phase 4 · not yet recruiting
- NCT07310836 — A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoin · not yet recruiting
- NCT06982664 — Effect of Preserving the Left Colic Artery on Proximal Bowel Perfusion · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06689189 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ningbo Medical Center Lihuili Hospital
- Last refreshed: 14 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06689189.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing